GlassScriptPhysician profile
Warren Mangel
NPI 1033196670
$4,843.43
in general payments reported to CMS, 2019-2025
31 companies · $1,060 in 2025
The $1,060 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $120 · 2021: $57.77 · 2022: $74.79 · 2023: $671 · 2024: $2,384 · 2025: $1,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,208 · Travel and Lodging: $908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,207.59 |
| Travel and Lodging | $907.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eclipse Technology Solutions INC. | $723.12 | 2023-2025 | |
| Arthrex, INC. | $600.30 | 2024 | |
| Stryker Corporation | $561.28 | 2019-2025 | Prostep Mica, Augment Injectable, Ortholoc 3di Crosscheck |
| Averitas Pharma INC. | $353.67 | 2023-2024 | Qutenza |
| Smith+Nephew, INC. | $331.48 | 2023-2025 | Pico 7, Stravix, Stravix Pl |
| Amgen INC. | $263.62 | 2024-2025 | Krystexxa |
| Abbvie INC. | $225.48 | 2019-2020 | |
| Kerecis Limited | $223.43 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Medtronic, INC. | $201.77 | 2024-2025 | Intellis Adaptivestim, Vanta Adaptivestim |
| Wright Medical Technology, INC. | $183.68 | 2019 | |
| Medshape, INC. | $144.38 | 2024 | Dynanail Helix, Washer, 15 Mm, Dynanail Mini, Dynanail |
| Treace Medical Concepts, INC. | $138.30 | 2024-2025 | |
| Inari Medical, INC. | $117.12 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Nevro Corp. | $91.04 | 2023 | Senza |
| Lifenet Health | $89.45 | 2023-2025 | Theragenesis Wound Matrix |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $76.33 | 2024-2025 | Physio-Stim |
| Grt US Holding, INC. | $74.79 | 2022 | |
| Biocomposites INC | $74.14 | 2025 | Stimulan |
| Acera Surgical, INC. | $49.20 | 2025 | Restrata Wound Matrix |
| Paratek Pharmaceuticals, INC. | $46.22 | 2025 | Nuzyra |
| Mimedx Group, INC. | $42.15 | 2025 | |
| Stimlabs LLC | $41.23 | 2025 | Corplex P |
| Integra Lifesciences Corporation | $40.57 | 2024-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Medical Device Business Services, INC. | $36.83 | 2025 | Motoband |
| Davol INC. | $21.58 | 2025 | Arista |
| Advanced Oxygen Therapy INC. | $19.15 | 2025 | Topical Oxygen Chamber For Extremities |
| Paragon 28, INC. | $18.11 | 2025 | Ttc Nail |
| Vertex Pharmaceuticals Incorporated | $15.85 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.78 | 2024 | Jublia |
| Kci USA, INC. | $12.87 | 2023 | Prevena |
| Merck Sharp & Dohme LLC | $12.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Mangel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.